S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AQST Aquestive Therapeutics Inc

3.52

0.00 (0.00%)

30 Dec 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

03/08/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

12/06/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Alexander Schobel

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Aquestive Therapeutics Charts.

Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Aquestive Therapeutics Charts.

Aquestive Therapeutics Inc News

Form 8-K - Current report
Friday 20 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
Friday 20 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 3 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
Tuesday 3 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 28 November 2024 (1 month ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (1 month ago) • Edgar (US Regulatory)

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Wednesday 13 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Saturday 9 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

More Aquestive Therapeutics Inc News Articles

Australia And New Zealan...

Newcrest Mining

AUD vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions